TY - JOUR
T1 - Polypeptide with electroactive endgroups as sensing platform for the abused drug ‘methamphetamine’ by bioelectrochemical method
AU - Demir, Bilal
AU - Yilmaz, Tulay
AU - Guler, Emine
AU - Gumus, Z. Pinar
AU - Akbulut, Huseyin
AU - Aldemir, Ebru
AU - Coskunol, Hakan
AU - Colak, Demet Goen
AU - Cianga, Ioan
AU - Yamada, Shuhei
AU - Timur, Suna
AU - Endo, Takeshi
AU - Yagci, Yusuf
N1 - Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Affinity-type sensors have emerged as outstanding platforms in the detection of diagnostic protein markers, nucleic acids and drugs. Thus, these novel platforms containing antibodies could be integrated into the monitoring systems for abused drugs. Herein, we established a novel detection platform for the analysis of a common illicit drug; methamphetamine (METH). Initially, a fluorescent-labeled polypeptide (EDOT-BTDA-Pala), derived from L-alanine N-carboxyanhydride (L-Ala-NCA) via ring-opening polymerization using 4,7-bis(2,3-dihydrothieno[3,4-b][1,4]dioxin-5-yl)benzo[c][1,2,5]thiadiazole-5,6-diamine (EDOT-NH2-BTDA) as initiator, was employed as a glassy carbon electrode (GCE) covering host, in order to immobilize the METH-selective antibody. Prior to the examination of analytical features, GCE/EDOT-BTDA-Pala/Antibody surface was successfully characterized in the way of electrochemical (cyclic voltammetry and electrochemical impedance spectroscopy) and microscopic techniques (scanning electron microscopy and fluorescence microscopy). As for the analytical characterization, linearity and limit of detection (LOD) were found as 10–100 µg/mL with an equation of y=0.0429x−0.2347, (R2=0.996) and 13.07 µg/mL, respectively. Moreover, sample application using artificial urine, saliva and serum samples spiked with METH (10, 25, 50 µg/mL) were performed and LC-MS/MS system was used for further confirmation. The described platform can be adapted to monitor the other types of abused drugs by using suitably selected biorecognition elements.
AB - Affinity-type sensors have emerged as outstanding platforms in the detection of diagnostic protein markers, nucleic acids and drugs. Thus, these novel platforms containing antibodies could be integrated into the monitoring systems for abused drugs. Herein, we established a novel detection platform for the analysis of a common illicit drug; methamphetamine (METH). Initially, a fluorescent-labeled polypeptide (EDOT-BTDA-Pala), derived from L-alanine N-carboxyanhydride (L-Ala-NCA) via ring-opening polymerization using 4,7-bis(2,3-dihydrothieno[3,4-b][1,4]dioxin-5-yl)benzo[c][1,2,5]thiadiazole-5,6-diamine (EDOT-NH2-BTDA) as initiator, was employed as a glassy carbon electrode (GCE) covering host, in order to immobilize the METH-selective antibody. Prior to the examination of analytical features, GCE/EDOT-BTDA-Pala/Antibody surface was successfully characterized in the way of electrochemical (cyclic voltammetry and electrochemical impedance spectroscopy) and microscopic techniques (scanning electron microscopy and fluorescence microscopy). As for the analytical characterization, linearity and limit of detection (LOD) were found as 10–100 µg/mL with an equation of y=0.0429x−0.2347, (R2=0.996) and 13.07 µg/mL, respectively. Moreover, sample application using artificial urine, saliva and serum samples spiked with METH (10, 25, 50 µg/mL) were performed and LC-MS/MS system was used for further confirmation. The described platform can be adapted to monitor the other types of abused drugs by using suitably selected biorecognition elements.
KW - Abused drug analysis
KW - Chromatography
KW - Immunosensor
KW - Methamphetamine
KW - Polypeptide
KW - Surface modification
UR - http://www.scopus.com/inward/record.url?scp=84988530826&partnerID=8YFLogxK
U2 - 10.1016/j.talanta.2016.09.042
DO - 10.1016/j.talanta.2016.09.042
M3 - Article
C2 - 27769482
AN - SCOPUS:84988530826
SN - 0039-9140
VL - 161
SP - 789
EP - 796
JO - Talanta
JF - Talanta
ER -